105 related articles for article (PubMed ID: 1442223)
1. [Therapeutic options in metastatic renal carcinoma].
Fernández Aparicio T; Miñana López B; Carrero V; Caballero J; Vazquez S; Calahorra L; Leiva O
Actas Urol Esp; 1992 Jul; 16(7):529-39. PubMed ID: 1442223
[TBL] [Abstract][Full Text] [Related]
2. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
[TBL] [Abstract][Full Text] [Related]
3. Management of metastatic renal cell carcinoma: current trends.
Mohammed A; Shergill I; Little B
Expert Rev Mol Diagn; 2009 Jan; 9(1):75-83. PubMed ID: 19099350
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
Kwan KG; Kapoor A
Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
[TBL] [Abstract][Full Text] [Related]
5. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC).
Brinkmann OA; Bruns F; Prott FJ; Hertle L
Anticancer Res; 1999; 19(2C):1583-7. PubMed ID: 10365150
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
7. [The therapy of metastatic renal carcinoma].
Rocca Rossetti S; Terrone C
Recenti Prog Med; 1999 Apr; 90(4):206-12. PubMed ID: 10354733
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
[TBL] [Abstract][Full Text] [Related]
9. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
10. [Neoadjuvant immunotherapy in non-metastatic renal adenocarcinoma].
Sánchez de la Muela P; Zudaire Bergera JJ; Robles García JE; Isa Kroon W; de Castro Barbosa F; Aguera Fernández L; Rosell Costa D; Berián Polo JM
Actas Urol Esp; 1990; 14(6):396-400. PubMed ID: 2080725
[TBL] [Abstract][Full Text] [Related]
11. New treatments for metastatic kidney cancer.
Mancuso A; Sternberg CN
Can J Urol; 2005 Feb; 12 Suppl 1():66-70; discussion 105. PubMed ID: 15780170
[TBL] [Abstract][Full Text] [Related]
12. Multimodality treatment of metastatic renal cell carcinoma.
Mickisch GH
Expert Rev Anticancer Ther; 2002 Dec; 2(6):681-5. PubMed ID: 12503214
[TBL] [Abstract][Full Text] [Related]
13. [Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology].
van Herpen CM; de Mulder PH
Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2613-8. PubMed ID: 10028361
[TBL] [Abstract][Full Text] [Related]
14. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
Belldegrun A; Shvarts O; Figlin RA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
[TBL] [Abstract][Full Text] [Related]
15. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M
J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789
[TBL] [Abstract][Full Text] [Related]
16. [Renal cell carcinoma--a current review].
Schmid HP; Szabo J
Praxis (Bern 1994); 1997 May; 86(20):837-43. PubMed ID: 9312811
[TBL] [Abstract][Full Text] [Related]
17. [Long-term results in the treatment of 100 metastatic hypernephroid carcinomas].
Falk W; Halama JM; Halama J
Strahlenther Onkol; 1990 Apr; 166(4):256-64. PubMed ID: 2139518
[TBL] [Abstract][Full Text] [Related]
18. Metastatic renal cell carcinoma: systemic treatment.
Abi-Aad AS; deKernion JB
Acta Urol Belg; 1996 May; 64(2):3-8. PubMed ID: 8701805
[No Abstract] [Full Text] [Related]
19. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
[TBL] [Abstract][Full Text] [Related]
20. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]